Articles by Park Min-ha
Park Min-ha
-
LG Innotek taps global talent to spur growth
LG Innotek, the advanced materials and components maker affiliated with LG Group, is speeding up efforts to recruit outstanding international students to enhance its global competitiveness. According to the company on Wednesday, a total of 31 international students either from foreign or Korean universities joined this year’s global internship program that was completed earlier this month. Under the five-week program, the students were allocated to diverse business divisions, including res
Industry Aug. 21, 2024
-
Daewoo E&C builds good management-labor relationship
Daewoo Engineering & Construction and its labor union have joined hands in the effort to create positive, amicable workplace culture for all workers and break through market challenges together. According to the South Korean builder on Tuesday, the management and union reached an agreement earlier this month to reform the company's personnel management systems. The plan includes simplifying the ranking system and upgrading personnel evaluation and wage schemes. They also completed this
Companies Aug. 20, 2024
-
Daewoong’s botulinum toxin debuts in Australia
Daewoong Pharmaceutical, South Korea’s leading drug maker, announced Monday the company officially launched its botulinum toxin, dubbed Nuceiva, in Australia in partnership with a Nasdaq-listed US company Evolus. Oceania is the fifth continent Daewoo Pharmaceutical has entered, after North America, South America, Europe and Asia, with its self-developed botulinum toxin. “Our market penetration into Australia will allow us to build on the momentum of expanding presence in the global m
Industry Aug. 19, 2024
-
NeuroBo Pharmaceuticals completes patient enrollment for phase 1 trial for antiobesity drug
NeuroBo Pharmaceuticals, the Nasdaq-listed biotech firm affiliated with South Korean drug maker DongA ST, announced Wednesday the company has completed patient enrollment for the first part of the phase 1 clinical trial for its antiobesity drug, dubbed DA-1726. DA-1726, designed to induce weight loss and glycemic control by simultaneously affecting GLP-1 and the glucagon receptor, is a drug candidate for treating obesity developed as an oxyntomodulin analog. In January, NeuroBo Pharmaceuticals
Industry Aug. 16, 2024
Most Popular
-
1
South Korean President Yoon Suk Yeol declares martial law
-
2
President Yoon Suk Yeol declares end to martial law after six-hour chaos
-
3
'Is this happening in 2024?' South Koreans in panic, disbelief
-
4
Opposition parties submit motion to impeach President Yoon Suk Yeol
-
5
Ruling party leader denounces Yoon's declaration of emergency martial law
-
6
What unfolded on Tuesday night in Seoul: A timeline
-
7
South Korea sees first martial law in over 40 years
-
8
Assembly passes motion to revoke martial law
-
9
Seoul defense chief calls meeting of key commanders
-
10
Yoon's senior aides resign en masse